Strickler, J. H., Cercek, A., Siena, S., André, T., Ng, K., Van Cutsem, E., … Bekaii-Saab, T. (2022). LBA27 Additional analyses of MOUNTAINEER: A phase II study of tucatinib and trastuzumab for HER2-positive mCRC. In Annals of Oncology (Vol. 33, pp. S1394–S1394). Elsevier BV. https://doi.org/10.1016/j.annonc.2022.08.023

Strickler, J. H., A. Cercek, S. Siena, T. André, K. Ng, E. Van Cutsem, C. Wu, et al. “LBA27 Additional analyses of MOUNTAINEER: A phase II study of tucatinib and trastuzumab for HER2-positive mCRC.” In Annals of Oncology, 33:S1394–S1394. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.08.023.

Strickler JH, Cercek A, Siena S, André T, Ng K, Van Cutsem E, et al. LBA27 Additional analyses of MOUNTAINEER: A phase II study of tucatinib and trastuzumab for HER2-positive mCRC. In: Annals of Oncology. Elsevier BV; 2022. p. S1394–S1394.

Strickler, J. H., et al. “LBA27 Additional analyses of MOUNTAINEER: A phase II study of tucatinib and trastuzumab for HER2-positive mCRC.” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S1394–S1394. Crossref, doi:10.1016/j.annonc.2022.08.023.

Strickler JH, Cercek A, Siena S, André T, Ng K, Van Cutsem E, Wu C, Paulson AS, Hubbard J, Coveler A, Fountzilas C, Kardosh A, Kasi PM, Lenz HJ, Ciombor KK, Fernandez MEE, Bajor DL, Stecher M, Feng W, Bekaii-Saab T. LBA27 Additional analyses of MOUNTAINEER: A phase II study of tucatinib and trastuzumab for HER2-positive mCRC. Annals of Oncology. Elsevier BV; 2022. p. S1394–S1394.